Source-grounded facts extracted from 4D Molecular Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
4D Molecular Therapeutics, Inc. shareholders approved Advisory, non-binding vote on named executive officers’ compensation at the 2026-06-17 meeting.
“Proposal 3. The Company’s stockholders approved, on an advisory, non-binding basis, the named executive officers’ compensation as disclosed in the Proxy Statement. FOR AGAINST ABSTAIN BROKER NON-VOTES 36,065,437 940,414 67,379 6,964,792”
4D Molecular Therapeutics, Inc. shareholders approved Ratification of selection of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-17 meeting.
“Proposal 2. The Company’s stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026. FOR AGAINST ABSTAIN 43,900,362 55,763 81,897”
4D Molecular Therapeutics, Inc. shareholders approved Election of Class III directors at the 2026-06-17 meeting.
“Proposal 1. The Company’s stockholders elected by a plurality of votes cast the Class III director nominees below to the Company’s Board of Directors to hold office until the 2029 Annual Meeting of Stockholders or until their successors are elected. NOMINEE FOR WITHHELD BROKER NON-VOTES Nancy Miller-Rich 35,880,028 1,193,202 6,964,792 John F. Milligan, Ph.D. 35,778,121 1,295,109 6,964,792 Shawn Cline Tomasello, MBA 30,508,706 6,564,524 6,964,792”
4D Molecular Therapeutics, Inc. reported the three months ended March 31, 2026 results: revenue $3.0 million, net income Net loss was $68.8 million.
“fund our operating expenses and capital expenditure requirements at least into the second half of 2028. Collaboration and License Revenue : Collaboration and license revenue was $3.0 million for the first quarter of 2026, as compared to an insignificant amount for the first quarter of 2025. The increase in revenue was primarily due to the clinical trial cost sharing”
4D Molecular Therapeutics, Inc. reported year ended December 31, 2025 results: revenue $85 million.
“role expanded to Chief Commercial & Business Officer • Entered Strategic Partnership with Otsuka Pharmaceutical Co., Ltd. for 4D-150 in Asia-Pacific Region o 4DMT received $85 million upfront cash payment in the fourth quarter of 2025 and expects to receive at least $50 million of cost sharing from Otsuka over the next three years for development activities”
4D Molecular Therapeutics, Inc. issued 1,750,000 shares of warrant to Biotechnology Value Fund, L.P. and its affiliates for exchanged 1,750,000 shares of the Company's common stock for a pre-funded warrant.
“BVF exchanged 1,750,000 shares of the Company’s common stock for a pre-funded warrant to acquire 1,750,000 shares of the Company’s common stock”
4D Molecular Therapeutics, Inc. issued 4,850,000 shares of warrant to RA Capital Healthcare Fund, L.P. for exchanged 4,850,000 shares of the Company's common stock for a pre-funded warrant.
“pursuant to which RA Capital exchanged 4,850,000 shares of the Company’s common stock for a pre-funded warrant to acquire 4,850,000 shares of the Company’s common stock”
4D Molecular Therapeutics, Inc.: Board amended and restated Bylaws to update advance notice procedures for business brought before a meeting and for nominations of directors (effective 2025-09-30).
“On September 30, 2025, the Board amended and restated the Company’s current amended and restated bylaws (the “Amended and Restated Bylaws”). The Amended and Restated Bylaws were amended to, among other revisions, update the advance notice procedures for business brought before a meeting and update the advance notice procedures for nominations of directors.”
4D Molecular Therapeutics, Inc. reported financial results for the three months ended March 31, 2024.
“4D Molecular Therapeutics, Inc. (“4DMT”) announced its financial results for the three months ended March 31, 2024.”
4D Molecular Therapeutics, Inc. reported financial results for the year ended December 31, 2023.
“On February 29, 2024, 4D Molecular Therapeutics, Inc. (“4DMT”) announced its financial results for the year ended December 31, 2023.”
Noriyuki Kasahara was appointed as Chief Scientific Officer at 4D Molecular Therapeutics, Inc..
“Effective as of January 2, 2024, Noriyuki Kasahara, M.D., Ph.D., has been appointed by the Board of Directors (the “Board”) of 4D Molecular Therapeutics, Inc. (the “Company”) as Chief Scientific Officer of the Company.”
4D Molecular Therapeutics, Inc.: Amended and restated bylaws to update advance notice procedures for business brought before a meeting and for nominations of directors (effective 2023-11-16).
“On November 16, 2023, the Board of Directors (the “Board”) of 4D Molecular Therapeutics, Inc. (the “Company”) amended and restated the Company’s current amended and restated bylaws (the “Amended and Restated Bylaws”).”
4D Molecular Therapeutics, Inc. reported financial results for the three months ended September 30, 2023.
“On November 9, 2023, 4D Molecular Therapeutics, Inc. (“4DMT”) announced its financial results for the three months ended September 30, 2023.”
Uneek Mehra was appointed as Chief Financial and Business Officer at 4D Molecular Therapeutics, Inc..
“announced that Uneek Mehra had joined the Company as Chief Financial and Business Officer, Principal Financial Officer, Principal Accounting Officer, and Assistant Secretary of the Company.”
August J. Moretti departed as Chief Financial Officer at 4D Molecular Therapeutics, Inc..
“announced that August J. Moretti will retire as Chief Financial Officer and Assistant Secretary of the Company, effective September 11, 2023.”
4D Molecular Therapeutics, Inc. reported financial results for three months ended June 30, 2023.
“On August 9, 2023, 4D Molecular Therapeutics, Inc. (“4DMT”) announced its financial results for the three months ended June 30, 2023.”
4D Molecular Therapeutics, Inc. shareholders approved Ratification of selection of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-05-23 meeting.
“Proposal 2. The Company’s stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023.”
4D Molecular Therapeutics, Inc. shareholders approved Election of Class III director nominees at the 2023-05-23 meeting.
“Proposal 1. The Company’s stockholders elected by a majority of votes cast the Class III director nominees below to the Company’s Board of Directors to hold office until the 2026 Annual Meeting of Stockholders or until their successors are elected.”
4D Molecular Therapeutics, Inc. reported three months ended March 31, 2023 results: net income $28.7 million.
“Net loss was $28.7 million for the quarter ended March 31, 2023”
4D Molecular Therapeutics, Inc. reported the year ended December 31, 2022 results: revenue $3.1 million.
“Total revenue was $3.1 million for 2022, as compared to $18.0 million for 2021.”
4D Molecular Therapeutics, Inc. reported the quarter ended September 30, 2022 results: revenue $0.5 million, net income $25.7 million.
“Revenue: Total revenue for the quarter ended September 30, 2022, was $0.5 million, as compared to $1.4 million for the quarter ended September 30, 2021.”
Fred Kamal changed role as President and Chief Operating Officer at 4D Molecular Therapeutics, Inc..
“appointed Fred Kamal, Ph.D., the Company’s current Chief Operating Officer and Chief Technical Officer, as President and Chief Operating Officer of the Company”
Noriyuki Kasahara was appointed as Class I director at 4D Molecular Therapeutics, Inc..
“appointed Noriyuki Kasahara, M.D., Ph.D., to the Board as a Class I director”
David Schaffer resigned as Director at 4D Molecular Therapeutics, Inc..
“On February 17, 2022, David Schaffer, Ph.D. delivered notice of his resignation from the Board of Directors (the "Board") of 4D Molecular Therapeutics, Inc. (the "Company") including his roles on the Nominating and Corporate Governance Committee and Science & Technology Committee, effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.